Trial Profile

A Phase 1 ascending oral dose study of SLV213 for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SLV 213 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; First in man
Sponsors Selva Therapeutics

Most Recent Events

22 May 2024 Results evaluating safety and pharmacokinetics of a single oral dose of SLV213 in healthy volunteers presented at the 120th International Conference of the American Thoracic Society.
02 Feb 2021 Results published in the Selva Therapeutics Media Release.
02 Feb 2021 Status changed from recruiting to completed, according to a Selva Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com